Nanotechnologies in drug delivery - An industrial perspective

Journal of Drug Delivery Science and Technology

Volumn 24, Issue 1, 2014, Pages 12-21

  Bazile, D V ^a  

^a SANOFI   (France)

Author keywords

Enhanced permeation; Nanotechnologies; Retention effect

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; APREPITANT; CAMPTOTHECIN; CYCLODEXTRIN; DOCETAXEL; DOXORUBICIN; FENOFIBRATE; LIVATAG; MEGESTROL; MEGESTROL ACETATE; NANOCAPSULE; NANOCRYSTAL; NANOPARTICLE; PACLITAXEL; PALIPERIDONE; RAPAMYCIN; SALICYLIC ACID; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG QUALITY; DRUG TARGETING; GAMMA IRRADIATION; GOLD STANDARD; HUMAN; MONONUCLEAR PHAGOCYTE; NANOENCAPSULATION; NANOMEDICINE; NANOMICS; NANOTECHNOLOGY; NONHUMAN; PHARMACOKINETICS; PHYSICAL CHEMISTRY; REPRODUCIBILITY; RETICULOENDOTHELIAL SYSTEM; REVIEW; SCALE UP; TOTAL QUALITY MANAGEMENT;

EID: 84894229105     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(14)50002-0     Document Type: Review

References (85)

1. Couvreur P., Vauthier C. - Nanotechnology: intelligent design to treat complex disease - Pharm. Res, 23 (7), 1417-1450, 2006. (Pubitemid 43993807)
2. Shegotar R., Müller R. H. - Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives - Int. J. Pharm, 399, 129-139, 2010.
3. Svenson S. - Clinical translation of nanomedicines. Current opinion in solid state and materials - Science, 16, 287-294, 2012.
4. Sheridan C. - Proof of concept for next-generation nanoparticle drugs in human - Nature Biotechnology, 30 (6), 471-473, 2012.
5. Etheridge M. L, Campbell S. A, Erdman A. G, Haynes C. L, Wolf S. M, McCullough J. - The big picture on nanomedicine: the state of investigational and approved nanomedicine products - Nanomedicine: Nanotechnology, Biology and Medicine, 9, 1-14, 2013.
6. Junghanns J-U. A. H. Müller R. H. - Nanocrystal technology, drug delivery and clinical applications - Int. J. Nanomed., 3 (3), 295-309, 2008.
7. Landry F.B., Bazile D.V., Spenlehauer G., Veillard M., Kreuter J. - Release of the fluorescent marker Prodan from poly(D,L-lactic acid) nanoparticles coated with albumin or polyvinyl alcohol in model digestive fluids (USP 22). - J. Control. Release, 44, 227-236, 1997. (Pubitemid 27039119)
8. Garber K. - Biologics inch toward cholesterol-lowering market. - Nature Biotechnology, 30 (4), 302-304, 2012.
9. Stern S.T., Hall J.B., Yu L.L., Wood L.J., Paciotti G.F., Tamarkin L., Long S.E., McNeil S.E. - Translational considerations for cancer nanomedicine. - J. Control. Release, 146, 164-174, 2010.
10. Crist R.M., Hall Grossman J., PatriA.K., Stern S.T., Dobrovolskaia M. A., Adiseshaiah P.P., Clogston J.D., McNeil S.E. - Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory - Integr. Biol., 5, 66-73, 2013.
11. Van den Mooter G. - The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate. - Drug. Discov. Today: Technology, 9 (2), e79-e85, 2012.
12. Brewster M.E., Loftsson T. - Cyclodextrins as pharmaceutical solubilizers. - Adv. Drug Deliv. Rev., 59, 645-666, 2007.
13. Paul L.D., Fish V., Mano T. - Bridging solubility between drug discovery and development. - Drug. Discov. Today, 17 (9/10), 486-494, 2012.
14. Zamboni W.C., Torchilin V., Patri A.K., Hrkach J., Stern S., Lee R., Nel A., Panaro N.J., Grodzinski P. - Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance - Clin. Cancer Res., 8(12), 1-13, 2012.
15. Torchilin V. - Tumor delivery of macromolecular drugs based on the EPR effect - Adv. Drug. Delivery Rev., 63, 131-135, 2011.
16. Acharya S., Sahoo S.K. - PLGAnanoparticles containing various anticancer agents and tumour delivery by EPR effect. - Adv. Drug. Delivery Rev., 63, 170-183, 2011.
17. Kreuter J. - Nanoparticulate systems for brain delivery of drugs. - Adv. Drug. Delivery Rev., 47, 65-81, 2001. (Pubitemid 32209233)
18. Wong H.L., Wu X.Y., Bendayan R. - Nanotechnological advances for the delivery of CNS therapeutics - Adv. Drug Deliv. Rev., 64, 686-700, 2011.
19. Costantino L., Boraschi D. - Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents ? Drug. Discov. Today, 17 (7/8), 367-378, 2012.
20. Tsuchihashi M., Harashima H., Kiwada H. - Development of a pharmacokinetic/pharmacodynamic (PK/PD)-simulation system for doxorubicin in long circulating liposomes in mice using peritoneal P388. - J. Control. Release, 61, 9-19, 1999. (Pubitemid 29406076)
21. Poulin P., Theil F-P. - Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition - J. Pharm. Sci, 91 (5), 1358-1370, 2002. (Pubitemid 34651198)
22. Nestorov I. - Whole body pharmacokinetic models. - Clin. Pharmacokinet., 42 (10), 883-908, 2003.
23. Li M., Al-Jamal K.T., Kostarelos K., Reineke J. - Physiologically based pharmacokinetic modeling of nanoparticles. - ACS Nano, 4(11), 6303-6317, 2010.
24. Amidon G.L., Lennemâs H., Shah V.P., Crison J.R. - Atheoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. - Pharm. Res, 12 (3), 413-420, 1995.
25. des Rieux A., Fievez V., Garinot M., Schneider Y.-J., Préat V. - Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. - J. Control. Release, 116, 1-27, 2006. (Pubitemid 44792295)
26. Trevaskis N.L., Charman W.N., Porter C.J.H. - Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. - Adv. Drug Delivery Rev., 60, 702-716, 2008.
27. Sahoo S.K., Dilnawaz F., Krishnakumar S. - Nanotechnology in ocular drug delivery. - Drug. Discov. Today, 13 (3/4), 144-151, 2008.
28. Bochot A., Fattal E. - Liposomes for intravitreal drug delivery: a state of the art. - J. Control. Release, 161, 628-634, 2012.
29. Poe D.S., Pyykko I. - Nanotechnology and the treatment of inner ear diseases. - WIREs Nanomedicine and Nanobiotechnology, 3, 212-221, 2011.
30. Wong J., Brugger A., Khare A., Chaubal M., Papadopoulos P., Rabinow B., Kipp J., Ning J. - Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. - Adv. Drug Delivery Rev., 60, 939-954, 2008.
31. Rabinow B.E. - Nanosuspensions in drug delivery. - Nature Reviews - Drug Discovery, 3, 785-796, 2004.
32. Tyner K., Sadrieh N. - Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review. - In: S.E. McNeil (Ed.), Characterization of Nanoparticles Intended for Drug Delivery, Method in Molecular Biology, vol. 697, 2011, doi 10.1007/978-1-60327-198-3.
33. Li S. M., Garreau H., Vert M. - Structure-property relationships in the case of the degradation of massive aliphatic poly-(-hydroxy acids) in aqueous media. Part 1. Poly(DL-lactic acid) - J. Mat. Sci. Mat. Med, 1, 123-130, 1990.
34. Landry F.B., Bazile D.V., Spenlehauer G., Veillard M., Kreuter J. - Degradation of poly(D, L-lactic acid) nanoparticles coated with albumin in model digestive fluids (USP 22). - Biomaterials, 17, 715-723, 1996. (Pubitemid 26091223)
35. Gao L., Zhang D., Chen M., Duana C., Dai W., Jia L., Zhaoa W. - Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. - Int. J. Pharm., 355, 321-327, 2008.
36. Szebeni J. - Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. - Toxicology, 216, 106-121, 2005. (Pubitemid 41712000)
37. Plard J.-P., Bazile D. - Comparison of the safety profiles of PLA50 and Me.PEG-PLA50 nanoparticles after single dose intravenous administration to rat. - Colloids and Surfaces B: Biointerfaces, 16, 173-183, 1999. (Pubitemid 29486804)
38. Hrkach J., Von Hoff D., Ali M.M., Andrianova E., Auer J., Campbell T., De Witt D., Figa M., Figueiredo M., Horhota A., Low S., McDonnell K., Peeke E., Retnarajan B., Sabnis A., Schnipper E., Song J.J., Song Y.h., Summa J., Tompsett D., Troiano G., Van Geen Hoven T., Wright J., LoRusso P., Kantoff P., Bander N.H., Sweeney C., Farokhzad O., Langer R., Zale S. - Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. - Sci. Transl. Med., 4, 128ra39, 2012, doi: 10.1126/scitranslmed.3003651.
39. Yang X.-Z., Dou S., Sun T.-M., Mao C.-Q., Wang H.-X., Wang J. - Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy. - J. Control. Release, 156, 203-211, 2011.
40. Adler A.F., Leong K.W. - Emerging links between surface nanotechnology and endocytosis: impact on non-viral gene delivery - Nano Today, 5, 553-569, 2010.
41. Kreuter J. - Nanoparticles - a historical perspective - Int. J. Pharm., 331, 1-10, 2007.
42. Bazile D.V., Ropert C., Huve P., Verrecchia T., Marlard M., Frydman A., Veillard M., Spenlehauer G. - Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats. - Biomaterials, 13 (15), 1093-1102, 1992. (Pubitemid 23022908)
43. Stolnik S., Ilium L., Davis S. S. - Long circulating microparticulate drug carriers. - Adv. Drug Delivery Rev., 16, 195-214, 1995.
44. Bazile D., Verrecchia T., Bassoulet M.-T., Marlard M., Spenlehauer G., Veillard M. - Ultradispersed polymer with rate and time control - J. Pharm. Sci. Technol., Japan, 53, Suppl., 10-13, 1993.
45. Gref R., Minamitake Y., Peracchia M.-T., Trubetskoy V., Torchilin V., Langer R. - Biodegradable long-circulating polymeric nanospheres. - Science, 263 (18), 1600-1603, 1994.
46. Bazile D., Prud'homme C., Bassoulet M.-T., Marlard M., Spenlehauer G., Veillard M. - Stealth Me.PEG-PLAnanoparticles avoid uptake by the mononuclear phagocytes system. - J. Pharm. Sci., 84 (4), 493-498, 1995.
47. Jeon S.I., Lee J.H., Andrade J.D., De Gennes P.-G. - Protein-surface interactions in the presence of polyethylene oxide - a simplified theory - J. Colloid Interface Sci., 142 (1), 149-158, 1991.
48. Vittaz M., Bazile D., Spenlehauer G., Verrecchia T., Veillard M., Puisieux F., Labarre D. - Effect of PEO surface density on longcirculating PLA-PEO nanoparticles which are very low complement activators. - Biomaterials, 17, 1575-1561, 1996.
49. Sahli H., Tapon-Bretaudiere J., Fischer A-M., Sternberg C., Spenlehauer G., Verrecchia T., Labarre D. - Interactions of poly(lactic acid) and poly(lactic acid-co-ethylene oxide) nanoparticles with the plasma factors of the coagulation system. - Biomaterials, 18, 281-288, 1997. (Pubitemid 27073047)
50. Hrkach J.S., Teresa Peracchia M.-T., Domb A., Lotans N., Langer R. - Nanotechnology for biomaterials engineering: structural characterization of amphiphilic polymeric nanoparticles by 1-H NMR spectroscopy. - Biomaterials, 18, 27-30, 1997. (Pubitemid 27029712)
51. Hagan S.A, Coombes A.G.A., Garnett M.C., Dunn S.E., Davies M.C., Ilium L., Davis S.S. - Polylactide-poly(ethylene glycol) copolymers as drug delivery systems. 1. Characterization of water dispersible micelle-forming systems. - Langmuir, 12, 2153-2161, 1996. (Pubitemid 126564672)
52. Riley T., Stolnik S., Heald C.R., Xiong C.D., Garnett M.C., Ilium L., Davis S.S. - Physicochemical evaluation of nanoparticles assembled from poly(lactic acid)-poly(ethylene glycol) (PLA-PEG) block copolymers as drug delivery vehicles. - Langmuir, 17, 3168-3174, 2001.
53. Heald C.R, Stolnik S., Kujawinski K.S., De Matteis C., Garnett M.C., Illum L., Davis S.S., Purkiss S.C., Barlow R.J., Gellert P.R. - Poly(lactic acid)-poly (ethylene oxide) (PLA-PEG) nanoparticles: NMR studies of the central solidlike PLA core and the liquid PEG corona. - Langmuir, 18, 3669-3675, 2002.
54. Moghimi S.M., Hunter A.C., Murray J.C. - Long-circulating and target-specific nanoparticles: theory to practice. - Pharmacol. Rev., 53, 283-318, 2001. (Pubitemid 32476118)
55. Owens III D.E., Peppas N.A. - Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles - Int. J. Pharm., 307, 93-102, 2006. (Pubitemid 41773257)
56. Vonarbourg A., Passirani C., Saulnier P., Benoit J.-P. - Parameters influencing the stealthiness of colloidal drug delivery systems - Biomaterials, 27, 4356-4373, 2006.
57. Desgouilles S., Vauthier C., Bazile D., Vacus J., Grossiord J.-L., Veillard M., Couvreur P. - The design of nanoparticles obtained by solvent evaporation: a comprehensive study. - Langmuir, 19, 9504-9510, 2003.
58. Riley T., Govender T., Stolnik S., Xiong C.D., Garnett M.C., Ilium L., Davis S.S. - Colloidal stability and drug incorporation aspects of micellar-like PLA-PEG nanoparticles. - Colloids and Surfaces B: Biointerfaces, 16, 147-159, 1999. (Pubitemid 29486802)
59. Govender T., Riley T., Ehtezazi T., Garnett M.C., Stolnik S., Illum L., Davis S.S. - Defining the drug incorporation properties of PLA-PEG nanoparticles. - Int. J. Pharm., 199, 95-110, 2000. (Pubitemid 30224509)
60. Karst D., Yang Y. - Method for predicting sorption of small drug molecules onto polylactide. - J. Biomed. Mater. Res, 88A, 255-263, 2009.
61. Szebeni J., Muggia F., Gabizon A., Barenholz Y. - Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. - Adv. Drug Delivery Rev., 63, 1020-1030, 2011.
62. Chanan-Khan A., Szebeni J., Savay S., Liebes L., Rafique N. M., Alving C.R., Muggia F.M. - Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. - Annals of Oncology, 14, 1430-1437, 2003. (Pubitemid 37185291)
63. Moghimi S.M., Wibroe P.P., Helvig S.Y., Farhangrazi Z.S., Hunter A.C. - Genomic perspectives in inter-individual adverse responses following nanomedicine administration: the way forward. - Adv. Drug Delivery Rev., 64, 1385-1393, 2012.
64. Zolnik B.S., Sadrieh N. - Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. - Adv. Drug Delivery Rev., 61, 422-427, 2009.
65. Zhang X.-Q., Xu X., Bertrand N., Pridgen E., Swami A., Farokhzad O.C. - Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. - Adv. Drug Delivery Rev., 64, 1363-1384, 2012.
66. Palucki M., Higgins J.D., Kwong E., Templeton A.C. - Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates. - J. Med. Chem, 53, 5897-5905, 2010.
67. Diehl K.-H., Hull R., Morton D., Pfister R., Rabemampianina Y., Smith D., Vidal J.-M., van de Vorstenbosch C. - A good practice guide to the administration of substances and removal of blood, including routes and volumes. -J. Applied Toxicol., 21, 15-23, 2001.
68. Stefani M., Coudane J., Vert M. - In vitro ageing and degradation of PEG-PLA diblock copolymer-based nanoparticles. - Polymer Degradation and Stability, 91, 2554-2559, 2006.
69. Müller R.H. Gohla S., Keck C.M. - State of the art of nanocrystals - Special features, production, nanotoxicology aspects and intracellular delivery. - Eur. J. Pharm. Biopharm., 78, 1-9, 2011.
70. Vauthier C., Bouchemal K. - Methods for the preparation and manufacture of polymeric nanoparticles. - Pharm. Res, 26, 1025-1057, 2009.
71. Vemuri S., Rhodes C.T. - Preparation and characterization of liposomes as therapeutic delivery systems: a review. - Pharmaceutica Acta Helvetiae, 70, 95-111, 1995.
72. Mehnert W., Mäder K. - Solid lipid nanoparticles Production, characterization and applications. - Adv. Drug Delivery Rev., 64, 83-101, 2012.
73. Heurtault B., Saulnier P., Pech B., Proust J.-E., Benoit J.-P. - A novel phase inversion-based process for the preparation of lipid nanocarriers. - Pharm. Res, 19 (6), 875-880, 2002. (Pubitemid 34692585)
74. Stefani M., Coudane J., Vert M. - Effects of polymerization conditions on the in vitro hydrolytic degradation of plaques of poly(DL-lactic acid-block-ethylene glycol) diblock copolymers. - Polymer Degradation and Stability, 91, 2853-2859, 2006.
75. Heurtault B., Saulnier P., Pech B., Proust J.-E., Benoit J.-P. - Physicochemical stability of colloidal lipid particles. - Biomaterials, 24, 4283-4300, 2003.
76. Abdelwahed W., Degobert G., Stainmesse S., Fessi H. - Freeze-drying of nanoparticles: formulation, process and storage considerations. - Adv. Drug Delivery Rev., 58, 1688-1713, 2006.
77. De Jaeghere F., Allemann E., Feijen J., Kissel T., Doelker E., Gurny R. - Freeze-drying and lyopreservation of diblock and triblock poly(lactic acid)-poly(ethylene oxide) (PLA-PEO) copolymer nanoparticles. - Pharm. Dev. Technol., 5 (4), 473-483, 2000.
78. Abdelwahed W., Degobert G., Fessi, H. - Investigation of nanocapsules stabilization by amorphous excipients during freeze-drying and storage. - Eur. J. Pharm. Biopharm., 63, 87-94, 2006.
79. Dulieu C., Bazile D. - Influence of lipid nanocapsules composition on their aptness to freeze-drying. - Pharm. Res., 22, 285-292, 2005. (Pubitemid 40487213)
80. Verrecchia T., Spenlehauer G., Bazile D. V, Murry-Brelier A., Archimbaud Y., Veillard M. - Non-stealth (poly(lactic acid/albumin) and stealth (poly(lactic acid-polyethylene glycol) nanoparticles as injectable drug carriers. - J. Control. Release, 36, 49-61, 1995.
81. Hu K., Shi Y., Jiang W., Han J., Huang S., Jiang X. - Lactoferrin conjugated PEG-PLGAnanoparticles for brain delivery preparation, characterization and efficacy in Parkinson's disease. - Int. J. Pharm., 415, 273-283, 2011.
82. Nance E.A., Woodworth G.F., Sailor K.A., Shih T.-Y., Xu Q., Swaminathan G., Xiang D., Eberhart C., Hanes J. - A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. - Sci. Transl. Med., 4, 149ra119, 2012.
83. Emile C., Bazile D., Herman F., Hélène C., Veillard M. - Encapsulation of oligonucleotides in stealth Me.PEG-PLA50 nanoparticles by complexation with structured oligopeptides. - Drug Delivery, 3, 187-195, 1996. (Pubitemid 26343100)
84. Yang X.-Z., Dou S., Wang Y.-C., Long H.-Y., Xiong M.-H., Mao C.-Q., Yao Y.-D., Wang J. - Single-step assembly of cationic lipid polymer hybrid nanoparticles for systemic delivery of siRNA. - ACS Nano, 6 (6), 4955-4965, 2012.
85. Bensaid F., Thillaye du Boullay O., Amgoune A., Pradel C., Harivardhan Reddy L., Didier E., Sablé S., Louit G., Bazile D., Bourissou D. - Y-shaped mPEG-PLA cabazitaxel conjugates: well-controlled synthesis by organocatalytic approach and self-assembly into interface drug-loaded core-corona nanoparticles. - Biomacromolecules, 14, 1189-1198, 2013.